PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Pharmabiz5d
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome
US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...
Investing4d
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock
This outcome represents a best-case scenario for Soleno, as it aligns with expectations and provides a strong foundation for the drug’s commercial launch. VYKAT XR is set to enter the U.S ...
Investing3d
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock
The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario for ...
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...
Soleno Therapeutics price target raised to $81 from $70 at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Soleno Therapeutics (SLNO) to $81 from $70 and keeps a Buy rating on ...
News-Medical.Net on MSN1d
US FDA approves first treatment for hyperphagia in Prader-Willi syndrome
The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).